S&P 500   3,215.60 (-0.66%)
DOW   26,587.48 (-0.66%)
QQQ   260.78 (-1.28%)
AAPL   105.23 (-1.76%)
MSFT   198.83 (-0.88%)
FB   246.41 (-1.05%)
GOOGL   1,398.23 (-0.79%)
AMZN   2,966.25 (-1.12%)
NVDA   478.74 (-1.28%)
TSLA   362.69 (-4.65%)
BABA   267.85 (-1.87%)
CGC   14.25 (-2.40%)
GE   6.09 (-0.33%)
MU   49.25 (-1.20%)
AMD   73.91 (-1.10%)
T   27.90 (+0.11%)
F   6.60 (-0.60%)
ACB   5.02 (-2.90%)
GILD   63.00 (-0.14%)
NFLX   466.58 (-0.86%)
DIS   121.80 (-1.20%)
BAC   23.25 (-0.04%)
BA   150.38 (-0.53%)
S&P 500   3,215.60 (-0.66%)
DOW   26,587.48 (-0.66%)
QQQ   260.78 (-1.28%)
AAPL   105.23 (-1.76%)
MSFT   198.83 (-0.88%)
FB   246.41 (-1.05%)
GOOGL   1,398.23 (-0.79%)
AMZN   2,966.25 (-1.12%)
NVDA   478.74 (-1.28%)
TSLA   362.69 (-4.65%)
BABA   267.85 (-1.87%)
CGC   14.25 (-2.40%)
GE   6.09 (-0.33%)
MU   49.25 (-1.20%)
AMD   73.91 (-1.10%)
T   27.90 (+0.11%)
F   6.60 (-0.60%)
ACB   5.02 (-2.90%)
GILD   63.00 (-0.14%)
NFLX   466.58 (-0.86%)
DIS   121.80 (-1.20%)
BAC   23.25 (-0.04%)
BA   150.38 (-0.53%)
S&P 500   3,215.60 (-0.66%)
DOW   26,587.48 (-0.66%)
QQQ   260.78 (-1.28%)
AAPL   105.23 (-1.76%)
MSFT   198.83 (-0.88%)
FB   246.41 (-1.05%)
GOOGL   1,398.23 (-0.79%)
AMZN   2,966.25 (-1.12%)
NVDA   478.74 (-1.28%)
TSLA   362.69 (-4.65%)
BABA   267.85 (-1.87%)
CGC   14.25 (-2.40%)
GE   6.09 (-0.33%)
MU   49.25 (-1.20%)
AMD   73.91 (-1.10%)
T   27.90 (+0.11%)
F   6.60 (-0.60%)
ACB   5.02 (-2.90%)
GILD   63.00 (-0.14%)
NFLX   466.58 (-0.86%)
DIS   121.80 (-1.20%)
BAC   23.25 (-0.04%)
BA   150.38 (-0.53%)
S&P 500   3,215.60 (-0.66%)
DOW   26,587.48 (-0.66%)
QQQ   260.78 (-1.28%)
AAPL   105.23 (-1.76%)
MSFT   198.83 (-0.88%)
FB   246.41 (-1.05%)
GOOGL   1,398.23 (-0.79%)
AMZN   2,966.25 (-1.12%)
NVDA   478.74 (-1.28%)
TSLA   362.69 (-4.65%)
BABA   267.85 (-1.87%)
CGC   14.25 (-2.40%)
GE   6.09 (-0.33%)
MU   49.25 (-1.20%)
AMD   73.91 (-1.10%)
T   27.90 (+0.11%)
F   6.60 (-0.60%)
ACB   5.02 (-2.90%)
GILD   63.00 (-0.14%)
NFLX   466.58 (-0.86%)
DIS   121.80 (-1.20%)
BAC   23.25 (-0.04%)
BA   150.38 (-0.53%)
Log in
NASDAQ:MLND

Millendo Therapeutics Stock Forecast, Price & News

$1.53
-0.08 (-4.97 %)
(As of 09/23/2020 12:00 AM ET)
Add
Compare
Today's Range
$1.53
Now: $1.53
$1.60
50-Day Range
$1.51
MA: $1.74
$1.96
52-Week Range
$1.26
Now: $1.53
$9.88
Volume181,381 shs
Average Volume831,393 shs
Market Capitalization$29.07 million
P/E RatioN/A
Dividend YieldN/A
Beta1.36
Millendo Therapeutics, Inc., a late-stage biopharmaceutical company, engages in the development of various treatments for orphan endocrine diseases in the United States. The company's lead product candidates include livoletide, a potential treatment for Prader-Willi syndrome; and nevanimibe, a potential treatment for patients with classic congenital adrenal hyperplasia. Millendo Therapeutics, Inc. is headquartered in Ann Arbor, Michigan.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 3.3Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 1.3 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.59 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:MLND
CUSIPN/A
CIKN/A
Phone734-845-9000

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$290,000.00
Book Value$3.28 per share

Profitability

Net Income$-44,570,000.00

Miscellaneous

Employees37
Market Cap$29.07 million
Next Earnings Date11/11/2020 (Estimated)
OptionableNot Optionable
$1.53
-0.08 (-4.97 %)
(As of 09/23/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive MLND News and Ratings via Email

Sign-up to receive the latest news and ratings for MLND and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Millendo Therapeutics (NASDAQ:MLND) Frequently Asked Questions

How has Millendo Therapeutics' stock price been impacted by Coronavirus?

Millendo Therapeutics' stock was trading at $6.58 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, MLND stock has decreased by 76.7% and is now trading at $1.53.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of Millendo Therapeutics?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Millendo Therapeutics in the last year. There are currently 2 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Millendo Therapeutics
.

When is Millendo Therapeutics' next earnings date?

Millendo Therapeutics is scheduled to release its next quarterly earnings announcement on Wednesday, November 11th 2020.
View our earnings forecast for Millendo Therapeutics
.

How were Millendo Therapeutics' earnings last quarter?

Millendo Therapeutics Inc (NASDAQ:MLND) posted its earnings results on Monday, August, 10th. The company reported ($0.56) earnings per share for the quarter, missing analysts' consensus estimates of ($0.55) by $0.01.
View Millendo Therapeutics' earnings history
.

What price target have analysts set for MLND?

5 analysts have issued 12 month price objectives for Millendo Therapeutics' shares. Their forecasts range from $2.00 to $6.00. On average, they expect Millendo Therapeutics' share price to reach $4.40 in the next twelve months. This suggests a possible upside of 187.6% from the stock's current price.
View analysts' price targets for Millendo Therapeutics
.

Are investors shorting Millendo Therapeutics?

Millendo Therapeutics saw a drop in short interest in the month of August. As of August 31st, there was short interest totaling 393,500 shares, a drop of 22.8% from the August 15th total of 509,700 shares. Based on an average trading volume of 1,130,000 shares, the short-interest ratio is presently 0.3 days.
View Millendo Therapeutics' Short Interest
.

Who are some of Millendo Therapeutics' key competitors?

What other stocks do shareholders of Millendo Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Millendo Therapeutics investors own include Allena Pharmaceuticals (alna), Matinas BioPharma (MTNB), Acasti Pharma (ACST), VYNE Therapeutics (vyne), Geron (GERN), Heat Biologics (HTBX), MEI Pharma (MEIP), Onconova Therapeutics (ONTX), TherapeuticsMD (TXMD) and DURECT (DRRX).

Who are Millendo Therapeutics' key executives?

Millendo Therapeutics' management team includes the following people:
  • Dr. Julia C. Owens Ph.D., CEO, Pres & Director (Age 47, Pay $702.8k)
  • Mr. Louis J. Arcudi III, M.B.A., MBA, Chief Financial Officer (Age 59, Pay $495.79k)
  • Dr. Ryan Zeidan Ph.D., Chief Devel. Officer (Age 40, Pay $511.69k)
  • Dr. Gary Hammer M.D., Ph.D., Co-Founder and Chairman of Scientific Advisory Board
  • Ms. Tamara Lynn Joseph, Gen. Counsel & Corp. Sec. (Age 57)

What is Millendo Therapeutics' stock symbol?

Millendo Therapeutics trades on the NASDAQ under the ticker symbol "MLND."

Who are Millendo Therapeutics' major shareholders?

Millendo Therapeutics' stock is owned by many different institutional and retail investors. Top institutional investors include Great Point Partners LLC (7.69%), Jacobs Levy Equity Management Inc. (1.06%), AWM Investment Company Inc. (1.05%), Bridgeway Capital Management Inc. (0.86%), Ikarian Capital LLC (0.71%) and Jane Street Group LLC (0.28%).

Which institutional investors are selling Millendo Therapeutics stock?

MLND stock was sold by a variety of institutional investors in the last quarter, including AWM Investment Company Inc., Great Point Partners LLC, and Caption Management LLC.

Which institutional investors are buying Millendo Therapeutics stock?

MLND stock was bought by a variety of institutional investors in the last quarter, including Ikarian Capital LLC, Jacobs Levy Equity Management Inc., Bridgeway Capital Management Inc., Jane Street Group LLC, Verition Fund Management LLC, Russell Investments Group Ltd., and Two Sigma Advisers LP.

How do I buy shares of Millendo Therapeutics?

Shares of MLND can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Millendo Therapeutics' stock price today?

One share of MLND stock can currently be purchased for approximately $1.53.

How big of a company is Millendo Therapeutics?

Millendo Therapeutics has a market capitalization of $29.07 million and generates $290,000.00 in revenue each year. The company earns $-44,570,000.00 in net income (profit) each year or ($3.25) on an earnings per share basis. Millendo Therapeutics employs 37 workers across the globe.

What is Millendo Therapeutics' official website?

The official website for Millendo Therapeutics is www.millendo.com.

How can I contact Millendo Therapeutics?

Millendo Therapeutics' mailing address is 110 MILLER AVENUE SUITE 100, ANN ARBOR MI, 48104. The company can be reached via phone at 734-845-9000 or via email at [email protected]

This page was last updated on 9/24/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.